Treatment of Irritable Bowel Syndrome Using Fecal Microbiota Transplantation: A Step Forward?

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2022 Jul 9

PMID 35809615

Authors

Michael Camilleri

Saam Dilmaghani

Affiliations

Soon will be listed here.

References

Spiegel B, Bolus R, Harris L, Lucak S, Naliboff B, Esrailian E . Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009; 30(11-12):1159-70. PMC: 2793273. DOI: 10.1111/j.1365-2036.2009.04144.x. View

Camilleri M . Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA. 2021; 325(9):865-877. DOI: 10.1001/jama.2020.22532. View

Pittayanon R, Lau J, Yuan Y, Leontiadis G, Tse F, Surette M . Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019; 157(1):97-108. DOI: 10.1053/j.gastro.2019.03.049. View

Yiannakou Y, Agrawal A, Allen P, Arebi N, Brown S, Eugenicos M . UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therap Adv Gastroenterol. 2018; 11:1756284818798791. PMC: 6170957. DOI: 10.1177/1756284818798791. View

Kazis L, Anderson J, Meenan R . Effect sizes for interpreting changes in health status. Med Care. 1989; 27(3 Suppl):S178-89. DOI: 10.1097/00005650-198903001-00015. View

Aroniadis O, Brandt L, Oneto C, Feuerstadt P, Sherman A, Wolkoff A . Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019; 4(9):675-685. DOI: 10.1016/S2468-1253(19)30198-0. View

Roalfe A, Roberts L, Wilson S . Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol. 2008; 8:30. PMC: 2496907. DOI: 10.1186/1471-230X-8-30. View

El-Salhy M, Winkel R, Casen C, Hausken T, Gilja O, Hatlebakk J . Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology. 2022; 163(4):982-994.e14. DOI: 10.1053/j.gastro.2022.06.020. View

Drossman D, Patrick D, Whitehead W, Toner B, Diamant N, Hu Y . Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000; 95(4):999-1007. DOI: 10.1111/j.1572-0241.2000.01941.x. View

10.

Levy M, Kolodziejczyk A, Thaiss C, Elinav E . Dysbiosis and the immune system. Nat Rev Immunol. 2017; 17(4):219-232. DOI: 10.1038/nri.2017.7. View

11.

Camilleri M, Chedid V . Actionable biomarkers: the key to resolving disorders of gastrointestinal function. Gut. 2020; 69(10):1730-1737. DOI: 10.1136/gutjnl-2019-320325. View

12.

El-Salhy M, Hatlebakk J, Gilja O, Kristoffersen A, Hausken T . Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2019; 69(5):859-867. PMC: 7229896. DOI: 10.1136/gutjnl-2019-319630. View

13.

Jaeschke R, Singer J, Guyatt G . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10(4):407-15. DOI: 10.1016/0197-2456(89)90005-6. View

14.

Dove L, Lembo A, Randall C, Fogel R, Andrae D, Davenport J . Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013; 145(2):329-38.e1. DOI: 10.1053/j.gastro.2013.04.006. View

15.

Francis C, Morris J, Whorwell P . The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11(2):395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x. View

16.

Farrar J, Young Jr J, Lamoreaux L, Werth J, Poole M . Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94(2):149-158. DOI: 10.1016/S0304-3959(01)00349-9. View

17.

Vancak V, Goldberg Y, Levine S . Guidelines to understand and compute the number needed to treat. Evid Based Ment Health. 2021; 24(4):131-136. PMC: 10231569. DOI: 10.1136/ebmental-2020-300232. View

18.

El-Salhy M, Kristoffersen A, Valeur J, Casen C, Hatlebakk J, Gilja O . Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2021; 34(1):e14200. DOI: 10.1111/nmo.14200. View